CEL-SCI ANNOUNCES PRESENTATION BY ITS CHIEF SCIENTIFIC OFFICER AT "TARGETED CANCER THERAPIES" CONFERENCE IN LONDON TODAY

Vienna, VA, May 27, 2010 --  CEL-SCI Corporation (NYSE AMEX: CVM) announced today that Dr. Eyal Talor, the Company's Chief Scientific Officer, will be giving a featured presentation titled "Latest Clinical Results using Multikine® Immunotherapy for Cancer" today at 3:05 pm London time at the "Targeted Cancer Therapies" conference in London, UK. The presentation will highlight Multikine's role as a potential treatment for head and neck cancer, and will include a discussion of Phase II clinical results and details on the Company's upcoming Phase III pivotal study.

This conference gathers the world's leading experts in oncology research and development to focus on innovative development of cancer drugs.

About Multikine

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received surgery, chemotherapy and/or radiation therapy, which can limit their effectiveness.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its L.E.A.P.S. technology platform.  The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu.  This investigational treatment is currently being tested in a clinical study at Johns Hopkins University.  The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland. 

For more information, please visit www.cel-sci.com.